Evidence map›Paper›PMID 39294422›Full record

ReviewFunctional & integrative genomics2024

lncRNA HOTAIR and Cardiovascular diseases.

Sina Taghvimi, Elahe Soltani Fard, Seyyed Hossein Khatami, Sara Zafaranchi Z M, Mortaza Taheri-Anganeh, Ahmad Movahedpour, Hassan Ghasemi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Functional & integrative genomics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sina Taghvimi *Department of Biology, Faculty of Sciences, Shahid Chamran University of Ahvaz, Ahvaz, Iran.
Elahe Soltani Fard *Student Research Committee, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Seyyed Hossein KhatamiStudent Research Committee, Department of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Sara Zafaranchi Z MDepartment of Molecular Medicine, School of Advanced Technologies in Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Mortaza Taheri-AnganehCellular and Molecular Research Center, Cellular and Molecular Medicine Research Institute, Urmia University of Medical Sciences, Urmia, Iran.
Ahmad MovahedpourCellular and Molecular Research Center, Yasuj University of Medical Sciences, Yasuj, Iran. ahmad.movahed14@gmail.com.
Hassan GhasemiResearch Center for Environmental Contaminants (RCEC), Abadan University of Medical Sciences, Abadan, Iran. clinicalbiochem.1365@gmail.com.

Funding

Abadan University of Medical Sciences 1402U-1734
6 · The paper itself

Abstract

Cardiovascular diseases (CVDs) a major contributor to global mortality rates, with a steadily rising prevalence observed across the world. Understanding the molecular mechanisms that underlie the signaling pathways implicated in the pathogenesis of CVDs represents a salient and advantageous avenue toward the development of precision and targeted therapeutics. A recent development in CVDs research is the discovery of long non-coding RNAs (lncRNAs), which are now understood to have crucial roles in the onset and development of several pathophysiological processes. The distinct expression patterns exhibited by lncRNAs in various CVDs contexts, present a significant opportunity for their utilization as both biomarkers and targets for therapeutic intervention. Among the various identified lncRNAs, HOX antisense intergenic RNA (HOTAIR) functions as signaling molecules that are significantly implicated in the pathogenesis of cardiovascular disorders in response to risk factors. HOTAIR has been observed to circulate within the bloodstream and possesses an integral epigenetic regulatory function in the transcriptional pathways of many diseases. Recent studies have suggested that HOTAIR offers promise as a biomarker for the detection and treatment of CVDs. The investigation on HOTAIR's role in CVDs, however, is still in its early phases. The goal of the current study is to give a thorough overview of recent developments in the field of analyzing the molecular mechanism of HOTAIR in controlling the pathophysiological processes of CVDs as well as its possible therapeutic uses.

Indexed as

Cardiovascular DiseasesRNA, Long NoncodingAnimalsBiomarkersEpigenesis, GeneticHumansSignal TransductionBiomarkersHOTAIR long untranslated RNA, humanRNA, Long NoncodingBiomarkerCardiovascular diseaseHOTAIRLong noncoding RNAs

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.